Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17333614 | INHIBITING INFLAMMATION WITH MILK OLIGOSACCHARIDES | May 2021 | December 2021 | Allow | 60 | 1 | 0 | Yes | No |
| 17254145 | CELL PROTECTIVE METHODS AND COMPOSITIONS | December 2020 | December 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 17116977 | HEPARANASE INHIBITORS FOR TREATMENT OF DIABETES | December 2020 | July 2022 | Allow | 19 | 1 | 1 | No | No |
| 15734500 | LD Heparin for the treatment and secondary prevention of ischemic stroke | December 2020 | July 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17106194 | Chitin Whisker-Enhanced Hyaluronic Acid Cell Scaffold and Preparation Method Thereof | November 2020 | March 2023 | Abandon | 27 | 2 | 0 | No | No |
| 17059982 | METHODS FOR PREVENTING A SERIOUS HEAL TH CONSEQUENCE AND/OR TISSUE DAMAGE AFTER EXPOSURE TO IONIZING RADIATION AND/OR CHEMOTHERAPY | November 2020 | February 2023 | Allow | 27 | 2 | 0 | No | No |
| 17059925 | PROCESSES FOR THE PREPARATION OF SUGAMMADEX | November 2020 | November 2022 | Allow | 23 | 2 | 1 | No | No |
| 17104502 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | November 2020 | October 2023 | Allow | 35 | 2 | 1 | No | No |
| 17103328 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | November 2020 | June 2023 | Allow | 30 | 2 | 1 | Yes | No |
| 17056283 | PROCESS FOR PREPARING CONCENTRATED SOLUTIONS OF STEVIOL GLYCOSIDES, AND USES | November 2020 | April 2024 | Allow | 41 | 2 | 0 | No | No |
| 17097977 | CYCLODEXTRIN DERIVATIVES REDUCING FLAVIVIRUS NS1-INDUCED ENDOTHELIAL HYPERPERMEABILITY AND VASCULAR LEAK | November 2020 | June 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17094432 | COMPOSITIONS COMPRISING 5-CHOLESTEN-3, 25-DIOL, 3-SULFATE (25HC3S) OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND AT LEAST ONE CYCLIC OLIGOSACCHARIDE | November 2020 | March 2022 | Allow | 17 | 1 | 0 | No | No |
| 17053867 | FIBROUS CELLULOSE AND METHOD FOR MANUFACTURING THE SAME, AND FIBROUS CELLULOSE COMPOSITE RESIN AND METHOD FOR MANUFACTURING THE SAME | November 2020 | March 2024 | Allow | 40 | 3 | 0 | Yes | No |
| 17083366 | STABLE IRON OLIGOSACCHARIDE COMPOUND | October 2020 | March 2024 | Allow | 40 | 4 | 1 | No | No |
| 17082976 | POROUS CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME | October 2020 | June 2022 | Allow | 20 | 1 | 0 | No | No |
| 17044230 | BIOACTIVE CARBOXYLIC ACID TYPE COMPOUND-POLYMER CONJUGATE, AND METHOD FOR MANUFACTURING THE SAME | September 2020 | August 2023 | Abandon | 34 | 2 | 1 | No | No |
| 17039483 | CYCLODEXTRIN DERIVATIVES IN THE TREATMENT OR PREVENTION OF LYSOSOMAL NEURODEGENERATIVE DISEASES | September 2020 | May 2022 | Allow | 19 | 0 | 0 | Yes | No |
| 17041215 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYROTAXANES | September 2020 | April 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17041103 | POLYSACCHARIDES FOR THE TREATMENT OF OCULAR CONDITIONS | September 2020 | May 2022 | Allow | 20 | 0 | 0 | Yes | No |
| 16982847 | HYALURONIC ACID SYNTHESIS PROMOTER, METHOD FOR PROMOTING HYALURONIC ACID SYNTHESIS, AND CELL EVALUATION METHOD | September 2020 | March 2023 | Abandon | 30 | 2 | 1 | No | No |
| 16978931 | N-Acylated Hyaluronic Acid for Hyperuricemia and Gouty Arthritis | September 2020 | February 2023 | Allow | 30 | 3 | 1 | No | No |
| 16976671 | TREATMENT OF POST-OPERATIVE JOINT PAIN WITH POLYSULFATED POLYSACCHARIDES | August 2020 | April 2023 | Allow | 31 | 3 | 0 | Yes | No |
| 16999157 | EXTRACTION METHOD OF CHITIN NANOCRYSTALS USING ELECTRON BEAM IRRADIATION AND CHITIN NANOCRYSTAL POWDER | August 2020 | December 2022 | Allow | 28 | 0 | 1 | Yes | No |
| 16968835 | TOLL-LIKE RECEPTOR LIGANDS | August 2020 | May 2022 | Allow | 21 | 0 | 1 | Yes | No |
| 16988641 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT COMPRISING GREEN BARLEY EXTRACT | August 2020 | April 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16935922 | STABILIZED AQUEOUS COMPOSITION COMPRISING CHONDROITIN SULFATE AND HYALURONIC ACID | July 2020 | June 2022 | Abandon | 23 | 2 | 0 | No | No |
| 16962592 | USE OF CARRIMYCIN OR ACTIVE INGREDIENTS THEREOF AND USE THEREOF | July 2020 | April 2022 | Allow | 60 | 1 | 1 | Yes | No |
| 16961555 | AMPHIPHILIC POLYSACCHARIDES, POLYSACCHARIDE-BASED HYDROGELS, AND METHODS OF MANUFACTURE | July 2020 | March 2022 | Allow | 20 | 0 | 1 | Yes | No |
| 16922492 | AGENT FOR IMPROVING OCULAR SUBJECTIVE SYMPTOMS AND METHOD THEREOF | July 2020 | August 2021 | Allow | 14 | 1 | 0 | Yes | No |
| 16922452 | AGENT FOR IMPROVING OCULAR SUBJECTIVE SYMPTOMS AND METHOD THEREOF | July 2020 | September 2021 | Allow | 14 | 1 | 0 | Yes | No |
| 16916569 | COSMETIC COMPOSITION FOR IMPROVED PENETRATION | June 2020 | September 2022 | Allow | 27 | 2 | 1 | No | No |
| 16911659 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | June 2020 | March 2022 | Abandon | 21 | 0 | 1 | No | No |
| 16956384 | METHOD FOR MODIFYING POLYSACCHARIDE MATERIAL BY SEQUENCED HOMOGENEOUS CHEMICAL FUNCTIONALISATION | June 2020 | March 2023 | Abandon | 33 | 2 | 1 | No | No |
| 16956172 | METHOD FOR IMPROVING THE ORAL BIOAVAILABILITY OF A DRUG | June 2020 | February 2023 | Allow | 32 | 3 | 0 | Yes | No |
| 16905750 | GLYCAN COMPOSITIONS AND USES THEREOF | June 2020 | November 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16904593 | Azithromycin Derivatives With Epithelial Barrier Enhancement Properties | June 2020 | September 2021 | Allow | 15 | 2 | 0 | No | No |
| 16898255 | TREATMENT OF CANCER | June 2020 | August 2023 | Abandon | 38 | 4 | 0 | Yes | No |
| 16767571 | Carboxyalkyl Chitosan | May 2020 | February 2023 | Allow | 32 | 3 | 0 | Yes | No |
| 16767572 | Anionically Charged Chitosan | May 2020 | September 2023 | Allow | 40 | 4 | 0 | Yes | No |
| 16763926 | HYALURONIC ACID DERIVATIVE MODIFIED WITH POLYETHYLENE GLYCOL | May 2020 | August 2022 | Allow | 27 | 1 | 0 | No | No |
| 16762147 | MIXTURE OF FUCOSYLATED CHONDROITIN SULFATE OLIGOSACCHARIDES AND METHOD FOR RAPIDLY PRODUCING THE SAME | May 2020 | September 2021 | Allow | 16 | 0 | 1 | Yes | No |
| 16761310 | PLATINUM COMPOUNDS FOR BINDING GUANINE QUADRUPLEXES | May 2020 | September 2022 | Allow | 28 | 0 | 0 | Yes | No |
| 16865661 | INHIBITORS OF PCSK9 FOR TREATMENT OF LIPOPROTEIN METABOLISM DISORDERS | May 2020 | March 2022 | Abandon | 22 | 1 | 1 | No | No |
| 16858762 | MUSCLE TREATMENT METHOD USING MYOD MUTANT | April 2020 | November 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16759063 | FETAL TISSUE EXTRACT, METHODS FOR PRODUCING THE SAME, AND THE USES THEREOF | April 2020 | September 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16857201 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OF RECURRENT URINARY TRACT INFECTION | April 2020 | July 2021 | Allow | 15 | 1 | 0 | No | No |
| 16846191 | TREATMENT OF CANCERS AND HEMATOPOIETIC STEM CELL DISORDERS PRIVILEGED BY CXCL12-CXCR4 INTERACTION | April 2020 | November 2021 | Abandon | 20 | 2 | 0 | No | No |
| 16843259 | 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE | April 2020 | April 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 16753500 | CROSSLINKING OF BIOPOLYMERS IN A SEMI-SOLID STATE | April 2020 | December 2021 | Allow | 20 | 1 | 0 | Yes | No |
| 16607870 | METHOD FOR PRODUCING CELLULOSE NANOFIBERS | April 2020 | May 2023 | Allow | 43 | 2 | 0 | Yes | No |
| 16652211 | PHARMACEUTICAL COMPOSITION FOR TREATING JOINT INFLAMMATION | March 2020 | November 2023 | Abandon | 44 | 5 | 0 | No | No |
| 16819770 | NON-ANTICOAGULANT SULFATED OR SULFONATED POLYSACCHARIDES | March 2020 | August 2021 | Abandon | 17 | 0 | 1 | No | No |
| 16811618 | Ophthalmic composition for treating dry eye and symptoms thereof | March 2020 | June 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16643494 | USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DYSREGULATION | February 2020 | June 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16801385 | GLUCOCEREBROSIDE TREATMENT OF DISEASE | February 2020 | April 2021 | Abandon | 14 | 1 | 0 | No | No |
| 16642291 | HEPARIN COMPOSITION FOR TREATING ISCHEMIA | February 2020 | December 2023 | Allow | 46 | 4 | 1 | Yes | No |
| 16792803 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 | February 2020 | February 2023 | Abandon | 36 | 2 | 0 | No | No |
| 16636266 | TREATING AND INHIBITING LEUKEMIA WITH NK-92 CELLS | February 2020 | January 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16747904 | METHOD OF INHIBITING INFLAMMATORY RESPONSE USING LIPOPOLYSACCHARIDE OF PARABACTEROIDES GOLDSTEINII | January 2020 | December 2021 | Allow | 23 | 2 | 0 | No | No |
| 16630174 | POTENTIATION OF ANTIBIOTIC EFFECT | January 2020 | September 2021 | Abandon | 20 | 5 | 1 | No | No |
| 16733945 | CYCLODEXTRIN DIMERS, COMPOSITIONS THEREOF, AND USES THEREOF | January 2020 | September 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16725566 | NITRIC OXIDE-RELEASING ANTIBACTERIAL POLYMERS AND SCAFFOLDS FABRICATED THEREFROM AND METHODS PERTAINING THERETO | December 2019 | February 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16625990 | IBANDRONATE CONJUGATES OF NUCLEOSIDE ANTIMETABOLITES | December 2019 | December 2021 | Allow | 23 | 2 | 0 | Yes | No |
| 16617368 | COMPOSITION FOR USE IN THE TREATMENT OF EXTRAOESOPHAGEAL GASTRIC REFLUX SYMPTOMS | November 2019 | September 2021 | Abandon | 22 | 1 | 1 | Yes | No |
| 16612011 | BLADDER INSTILLATION COMPOSITION CONTAINING CHONDROITIN SULFATE (20 MG/ML), HYALURONIC ACID (16 MG/ML) AND A PHOSPHATE BUFFER (PH 6.1 TO 7.9) WITH INCREASED STORAGE STABILITY FOR TREATING CYSTITIS | November 2019 | August 2021 | Allow | 21 | 1 | 0 | No | No |
| 16608677 | TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR | October 2019 | April 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16664722 | CYPHOMYCIN, COMPOSITIONS AND USES THEREOF | October 2019 | February 2021 | Allow | 15 | 1 | 0 | Yes | No |
| 16663217 | Cholesterol Lowering Drugs for the Treatment of Hepatic Encephalopathy | October 2019 | July 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16606485 | VITAMIN C AND DOXYCYCLINE: A SYNTHETIC LETHAL COMBINATION THERAPY FOR ERADICATING CANCER STEM CELLS (CSCS) | October 2019 | August 2021 | Allow | 22 | 1 | 1 | Yes | No |
| 16655004 | SIALYLATION-INCREASING THERAPIES FOR DISEASES ASSOCIATED WITH OXIDATIVE STRESS | October 2019 | April 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16604550 | PROCESS FOR MAKING PULLULAN | October 2019 | January 2022 | Allow | 27 | 1 | 1 | No | No |
| 16500967 | USE OF CARRIMYCIN AND PHARMACEUTICALLY ACCEPTABLE SALTS OF CARRIMYCIN IN MANUFACTURING MEDICAMENT FOR TREATING AND/OR PREVENTING TUMOR | October 2019 | March 2021 | Allow | 18 | 1 | 0 | No | No |
| 16500935 | TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS | October 2019 | March 2022 | Abandon | 29 | 3 | 0 | No | No |
| 16500755 | COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING A PATHOGEN AND/OR MODIFYING MUCUS | October 2019 | January 2022 | Allow | 27 | 3 | 0 | Yes | No |
| 16497696 | NITRIC OXIDE-RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO | September 2019 | March 2023 | Allow | 42 | 3 | 1 | Yes | No |
| 16577691 | MIXTURE OF NON-DIGESTIBLE OLIGOSACCHARIDES FOR STIMULATING THE IMMUNE SYSTEM | September 2019 | April 2021 | Allow | 19 | 2 | 0 | No | No |
| 16495967 | HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMECEUTICAL USES | September 2019 | August 2021 | Allow | 23 | 1 | 1 | Yes | No |
| 16494746 | Functionalized Scaffold To Promote Meniscus Repair | September 2019 | December 2022 | Abandon | 39 | 0 | 1 | No | No |
| 16492218 | NOVEL VISCOELASTIC SOLUTION AND USE THEREOF IN RHUMATOLOGY | September 2019 | May 2021 | Allow | 20 | 1 | 1 | Yes | No |
| 16549405 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA WITH IVERMECTIN | August 2019 | March 2021 | Abandon | 19 | 1 | 0 | No | No |
| 16486678 | TRIAZOLE-CONTAINING MACROLIDES AND OPHTHALMIC USES THEREFOR | August 2019 | February 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16541660 | TREATMENT OF MYELOSUPPRESSION | August 2019 | September 2021 | Allow | 25 | 2 | 0 | Yes | No |
| 16538875 | SEPARATION MEDIUM, USE FOR SEPARATION MEDIUM, STEVIOL GLYCOSIDE SEPARATION METHOD USING SEPARATION MEDIUM, AND STEVIOL GLYCOSIDE PRODUCTION METHOD USING SEPARATION METHOD | August 2019 | August 2021 | Abandon | 24 | 2 | 1 | No | No |
| 16477711 | PHARMACEUTICAL COMPOSITION CONTAINING SULGLYCOTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR PREVENTING OR TREATING DRY EYE | July 2019 | May 2020 | Allow | 10 | 0 | 0 | No | No |
| 16460511 | COMPOSITIONS OF HYALURONAN WITH HIGH ELASTICITY AND USES THEREOF | July 2019 | October 2020 | Allow | 16 | 1 | 0 | No | No |
| 16475493 | USE OF ALBIFLORIN AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITOR | July 2019 | July 2021 | Abandon | 24 | 2 | 0 | No | No |
| 16459015 | NITRIC OXIDE-RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO | July 2019 | September 2020 | Allow | 15 | 2 | 1 | Yes | No |
| 16456553 | NON-ANTICOAGULANT SULFATED OR SULFONATED POLYSACCHARIDES | June 2019 | April 2020 | Abandon | 10 | 1 | 0 | No | No |
| 16453460 | POLYPHENOL GLYCOSIDE-CONTAINING COMPOSITION | June 2019 | July 2021 | Abandon | 25 | 2 | 0 | No | No |
| 16448180 | COMBINATION OF CROSS-LINKED HYALURONIC ACIDS AND METHOD OF PREPARING THE SAME | June 2019 | July 2021 | Allow | 25 | 1 | 1 | Yes | No |
| 16468345 | ALLULOSE-CONTAINING COMPOSITION FOR PROMOTING EXCRETION OF VEGETABLE LIPIDS FROM THE BODY | June 2019 | August 2021 | Allow | 26 | 3 | 0 | No | No |
| 16435680 | ORAL ANTICANCER PRODRUGS, THEIR PREPARATION METHODS AND APPLICATIONS | June 2019 | July 2023 | Abandon | 49 | 4 | 0 | No | No |
| 16465536 | SILYLATED DERIVATIVES OF RESVERATROL AND THE USE THEREOF IN NEURODEGENERATIVE, NEUROLOGICAL OR INFLAMMATORY DISEASES | May 2019 | October 2021 | Allow | 29 | 2 | 1 | No | No |
| 16418758 | N-ACETYLATED SIALIC ACIDS AND RELATED SIALOSIDES | May 2019 | June 2021 | Allow | 25 | 1 | 1 | Yes | No |
| 16417488 | N-ACETYL MANNOSAMMINE AS A THERAPEUTIC AGENT | May 2019 | November 2020 | Allow | 18 | 2 | 0 | Yes | No |
| 16462129 | OPHTHALMIC COMPOSITIONS COMPRISING A CYCLODEXTRIN AS SOLE ACTIVE AGENT | May 2019 | December 2020 | Abandon | 19 | 1 | 0 | No | No |
| 16407865 | AMPHIPHILIC POLYMER AND MANUFACTURING METHOD THEREOF, USE OF AMPHIPHILIC POLYMER AS CONTACT LENS MATERIAL, CONTACT LENS MATERIAL INCLUDING AMPHIPHILIC POLYMER | May 2019 | January 2021 | Allow | 21 | 1 | 1 | No | No |
| 16348432 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF ACSL4-OVEREXPRESSING TUMORS | May 2019 | July 2021 | Abandon | 26 | 2 | 1 | Yes | No |
| 16370679 | IMPLANTS FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN | March 2019 | September 2022 | Abandon | 42 | 2 | 0 | No | Yes |
| 16367233 | SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN TREATING PROLIFERATIVE DISORDERS | March 2019 | October 2020 | Abandon | 18 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MAIER, LEIGH C.
With a 6.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 5.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MAIER, LEIGH C works in Art Unit 1623 and has examined 581 patent applications in our dataset. With an allowance rate of 40.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner MAIER, LEIGH C's allowance rate of 40.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MAIER, LEIGH C receive 1.99 office actions before reaching final disposition. This places the examiner in the 46% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MAIER, LEIGH C is 31 months. This places the examiner in the 53% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +47.8% benefit to allowance rate for applications examined by MAIER, LEIGH C. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 75.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 61% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 15% percentile among all examiners. Of these withdrawals, 53.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 55.8% are granted (fully or in part). This grant rate is in the 55% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.